Ignite Creation Date:
2025-12-24 @ 4:51 PM
Ignite Modification Date:
2026-02-20 @ 5:37 PM
Study NCT ID:
NCT05846750
Status:
RECRUITING
Last Update Posted:
2023-07-19
First Post:
2023-04-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
BDHMZL2023
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None